Intragastric Balloon Market Analysis

Intragastric Balloon Market Analysis

The single intragastric balloon segment accounted for USD 23.2 million in 2021 led by the rising awareness coupled with increasing usage of non-invasive procedures. Also, increasing number of obese patients worldwide and improved product design will accelerate the segment growth during the forecast period. Furthermore, various technological advances for improving patient outcomes and development of next generation intragastric balloon will spur the industry expansion in the coming years. However, with the introduction of dual and triple intragastric balloons, single intragastric balloons will exhibit sluggish the industry progression during the forecast period.
 

Saline-filled balloon segment held more than 63% of the market share in 2021 impelled by the advantages associated with saline-filled intragastric balloon. The advantages include ability to reduce weight more effectively and quick detection of silicone balloon deflation due to methylene blue dye. The dye helps in identifying if the balloon is ruptured. This non-invasive and non-pharmacological approach helps in reduction of around 15 to 25 kg weight.
 

The hospitals segment accounted for 35.5% of revenue share in 2021 owing to the growing disease burden including obesity coupled with increasing healthcare investments worldwide. Moreover, government policies for implementation of high-quality patient care will attract large number of patients in hospitals to seek treatments. Also, new clinical trials conducted in multi-specialty hospitals will provide opportunities to the patients to explore new experimental therapies, thereby augmenting the segment value.
 

North America intragastric balloon market size was over USD 12.5 million in 2021 and is predicted to witness 12.1% growth rate through 2028. The key factors driving the regional growth includes rising prevalence of obesity coupled with high adoption of non-surgical treatments. For instance, according to 2017 obesity update by the Organization for Economic Co-operation and Development (OECD), about 47% of the total population in U.S. is suffering from obesity. Similarly, according to Canadian Institute for Health Information, obesity is one of the major health issues in Canada, affecting about 1 in 5 Canadian adults. Thus, as number of obese patients will increase in U.S. and Canada, the demand for obesity treatment will also increase, thereby leading to industry demand of intragastric balloon in North America region.